Prognostic Effect of Sarcopenia in Hepatocellular Carcinoma Patients Targeted with Interventional Therapy Combined with Immunotherapy and Targeted Therapy (vol 11, pg 175, 2024)

被引：0
作者：
Yang, H.
Cong, T.
Luo, Y.
Yang, C.
Ren, J.
Li, X.
机构：
来源：
JOURNAL OF HEPATOCELLULAR CARCINOMA | 2024年 / 11卷
基金：
中国国家自然科学基金;
关键词：
D O I：
10.2147/JHC.S467902
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：563 / 563
页数：1
相关论文
共 50 条
[41]   TP53 and RET may serve as biomarkers of prognostic evaluation and targeted therapy in hepatocellular carcinoma (vol 37, pg 2215, 2017) [J].
Ye, Song ;
Zhao, Xin-Yi ;
Hu, Xiao-Ge ;
Li, Tang ;
Xu, Qiu-Ran ;
Yang, Huan-Ming ;
Huang, Dong-Sheng ;
Yang, Liu .
ONCOLOGY REPORTS, 2022, 48 (05)
[42]   Depth of Radiographic Response as an Independent Prognostic Factor for Patients with Initially Unresectable Hepatocellular Carcinoma Receiving Hepatectomy following Targeted Therapy plus Immunotherapy [J].
Xu, Bin ;
Wang, Lu-Na ;
Wang, Zi-Yi ;
He, Tian ;
Zhu, Xiao-Dong ;
Shen, Ying-Hao ;
Zhou, Jian ;
Fan, Jia ;
Sun, Hui-Chuan ;
Huang, Cheng .
LIVER CANCER, 2025, 14 (02) :142-157
[43]   Combining immunotherapy/targeted therapy with hepatic artery chemo-infusion in treating patients with advanced hepatocellular carcinoma [J].
Son, Sam Y. ;
Yarmohammadi, Hooman .
CHINESE CLINICAL ONCOLOGY, 2024, 13 (05)
[44]   Combined targeted therapy and immunotherapy in anaplastic thyroid carcinoma with distant metastasis: A case report [J].
Dong-Xu Ma ;
Xiu-Ping Ding ;
Chi Zhang ;
Peng Shi .
World Journal of Clinical Cases, 2022, (12) :3849-3855
[45]   Combined targeted therapy and immunotherapy in anaplastic thyroid carcinoma with distant metastasis: A case report [J].
Ma, Dong-Xu ;
Ding, Xiu-Ping ;
Zhang, Chi ;
Shi, Peng .
WORLD JOURNAL OF CLINICAL CASES, 2022, 10 (12) :3849-3855
[46]   Addition of Salvage Immunotherapy to Targeted Therapy in Patients with Metastatic Renal Cell Carcinoma [J].
Dawsey, Scott J. ;
Ornstein, Moshe C. .
CURRENT ONCOLOGY, 2021, 28 (06) :5019-5024
[47]   Combined Targeted Therapy in the Treatment of Recurrent Fibrolamellar Hepatocellular Carcinoma: Clinical Case Description [J].
Adyrov, M. .
PEDIATRIC BLOOD & CANCER, 2019, 66 :S601-S601
[48]   Clinical Efficacy and Safety of transarterial chemoembolization Combined with Targeted Therapy for primary hepatocellular carcinoma [J].
Wang, Xiao ;
Zhang, Dan ;
Li, Kang ;
Guo, Peng ;
Lei, Zhi-xiong .
PAKISTAN JOURNAL OF MEDICAL SCIENCES, 2024, 40 (08) :1663-1668
[49]   MAFLD-related hepatocellular carcinoma: Exploring the potent combination of immunotherapy and molecular targeted therapy [J].
Guo, Ziwei ;
Yao, Ziang ;
Huang, Bohao ;
Wu, Dongjie ;
Li, Yanbo ;
Chen, Xiaohan ;
Lu, Yanping ;
Wang, Li ;
Lv, Wenliang .
INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 140
[50]   NFκB activation demarcates a subset of hepatocellular carcinoma patients for targeted therapy [J].
Vignesh Ramesh ;
Karthikeyan Selvarasu ;
Jaishree Pandian ;
Soundarajan Myilsamy ;
Chidambaranathan Shanmugasundaram ;
Kumaresan Ganesan .
Cellular Oncology, 2016, 39 :523-536
12345